R&D

Overview

AGM-331 AGM-130 AGM-380 AGM-290 AGM-212 AGM-217 AGM-260
Anti-cancer Drug AGM-130
An indirubin derivative, a potent inhibitor of CDK (cyclin dependent kinase) 1, 2, 5, 6, and 9 as well as GSK3β, significantly inhibits the proliferation of various cancer cells by arresting the G2/M phase of the cell cycle leading to apoptosis
  • Phase 1 study finished
    • - Finished the schedule up to Cohort 5 without any drug related SAE (serious adverse effect)
    • - Dose-dependent systemic exposures were observed.

  • Phase 1b/2a is planned
    (combination with existing chemotherapy)

  • Administration of AGM-130 in various xenograft cancer animal models resulted in substantial decrease of tumor progression with excellent short-term and long-term toxicity profiles.

  • Specifically, AGM-130 as a single agent shows dramatic efficacy in tumor xenograft animal models with metastatic triple negative breast cancer (TNBC) and tamoxifen-resistant ER-positive breast cancer cell lines.

  • Synergistic effect with current 2nd line TNBC therapies
    1) in vitro synergistic effect was noted when combined with cisplatin
    2) in xenograft model, strong synergism was demonstrated with cisplatin